255 results about "Liver disease" patented technology

The present invention relates to a novel lipid compound for tissue-specific delivery, and a lipid nano-particle (LNP) composition comprising the same, the lipid nano-particle comprising a modified lipid compound as a component, according to the present invention, internal active substances are selectively delivered into cells of specific tissues such as lymph nodes, spleen, retina, cancer, brain, liver and the like in vivo, thereby preventing side effects and safely exhibiting a desired level of effect. The tissue-specific non-viral LNP delivery vectors can be effectively used for prevention of infectious diseases and treatment of rare and refractory (hereditary) diseases (diseases which are effectively and selectively delivered to in-vivo targeted sites, such as macular degeneration, diabetic retinal degeneration, hereditary retinal degeneration, cancer, cerebral diseases, liver diseases and the like).

The present invention provides an isolated Akkermansia muciniphila strain, composition comprising the same, and use thereof, which can be used for treating, preventing, or alleviating obesity, metabolic disorders induced by obesity, diabetes, inflammation, liver and kidney diseases, liver diseases, cardiovascular and cerebrovascular diseases, brain aging, tumors, etc. Additionally, it can be used for preventing and treating metabolic disorders after discontinuation of GLP-1 receptor agonist drugs, preventing weight rebound and blood glucose rebound, and maintaining glucose homeostasis.

The invention discloses application of a compound AZD5718 in preparation of a medicine for preventing and / or treating cholestatic liver diseases, and belongs to the field of biological medicines. The compound AZD5718 can effectively improve hepatocyte damage and bile metabolism disorder caused by Mdr2 gene deletion, provides solid experimental data support for developing novel drugs for treating cholestatic liver diseases, is expected to provide differentiated therapeutic drug choices for clinic, and has important medical value and social significance.

The present application relates to the application of nucleic acid molecules in the preparation of drugs for treating liver diseases; the nucleic acid molecules have one or more of the following conditions: comprising any one or more of miR-302s; comprising any one or more of miR-302s, mimics or derivatives of any one or more of miR-302s, the mimics or derivatives have a core fragment shown in SEQ ID No. 1 and have the same or similar function as any one or more of the miR-302s members; comprising a miRNA precursor, which can be processed into any one or more of miR-302s, mimics or derivatives in the host; comprising a polynucleotide fragment, which can be transcribed into the miRNA precursor in the host; comprising an expression vector containing a polynucleotide fragment. The present application provides a new idea for the treatment of liver diseases.

1. Name of the product in this design: Liver Disease Treatment Instrument. 2. Purpose of this design: For the treatment of liver diseases. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model.

Disclosed are novel compounds that are antagonists of the human GPR39 protein. Disclosed are pharmaceutical compositions of antagonists of the human GPR39 protein and methods of use. In particular, disclosed herein are methods of using the antagonists to treat diseases or conditions, including cardiovascular conditions, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, blood disorders, neurological disorders, and respiratory diseases.

The invention discloses a whole course follow-up visit and compliance management system for hepatopathy patients, which belongs to the technical field of medical health information management and comprises a multi-dimensional risk layering module, a self-adaptive follow-up visit scheduling module, a behavior intervention engine module and a closed-loop effect evaluation module. The multi-dimensional risk layering module performs feature fusion and risk layering based on clinical, behavior and psychological data; the adaptive follow-up scheduling module dynamically adjusts the follow-up frequency according to the risk level; the behavior intervention engine module generates a personalized intervention scheme based on a habit formation theory; the closed-loop effect evaluation module calculates compliance improvement indexes and generates optimization parameters, the four modules form a deep coupling closed-loop system, self-adaptive optimization is achieved, the treatment compliance rate of a patient can be increased, and the treatment effect can be remarkably improved.

Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such as NAFLD or NASH, or drug induced liver injury (DILI).

The present invention provides methods of using non-naturally occurring melanocortin analogs to increase body weight and / or increase food consumption in a subject having a kidney disease and / or a liver disease (e.g., chronic kidney disease, renal failure, non-alcoholic fatty liver disease (NAFLD)). Also provided are methods of stimulating appetite in a subject via administration of a non-naturally occurring melanocortin analogue. The non-naturally occurring melanocortin analogs may be present in pharmaceutical compositions and delivered via parenteral administration (e.g., subcutaneous injection). The methods improve appetite, increase food consumption, increase body weight, muscle mass, and / or fat mass in the subject.

This specification relates to crystalline forms of ((2R,6S)-2,6-dimethylmorpholino)(5-(2,4,5-trifluoro-3-hydroxyphenyl)-1,2,4-oxadiazol-3-yl)methanone, pharmaceutical compositions containing the crystalline forms, and uses of the crystalline forms in the treatment of diseases such as liver disease. Formula (I). (I)

The application discloses a preparation method and application of large-size human liver organoids, and belongs to the technical field of cell culture. In the application, 2D culture mature human primary liver parenchymal cells with different cell amounts are resuspended by using a hepatocyte maturation medium HIM, and are added into a U-shaped bottom 96-hole plate for low-oxygen static culture. After the cells are aggregated, the cells are cultured in normal oxygen and are shaken, so that large-size human liver organoids with different cell contents are prepared. The method does not need biological materials, and can induce human primary liver parenchymal cells to self-assemble and construct functional liver organoids with high uniformity in scale through specific culture conditions. The method solves the problems of large batch difference, high heterogeneity and dedifferentiation in the prior art, and can be widely applied to drug hepatotoxicity testing, in-vitro modeling of liver diseases and development of a bioartificial liver system.

Described are methods for treating alpha-1 antitrypsin deficiency (AATD) in a human patient in need of treatment, using pharmaceutical compositions that include AAT RNAi agents. The pharmaceutical compositions disclosed herein that include AAT RNAi agents, when administered to a human patient in need thereof, treat liver diseases associated with AAT deficiency such as chronic hepatitis, cirrhosis, increased risk of hepatocellular carcinoma, transaminitis, cholestasis, fibrosis, fulminant hepatic failure, and other liver-related diseases.

The invention discloses application of Psammatlysene D and a derivative thereof in preparation of a medicine for resisting chronic liver diseases, and belongs to the technical field of medicines. The technical scheme of the invention comprises the application of the Psammaglyene D in preparation of a product for resisting chronic liver diseases. The Psammatlyene D can inhibit the growth of LX2 cells, reduce liver function indexes ALT and AST, and relieve the degree of hepatic fibrosis in a mouse body; the growth of liver cancer cells can be inhibited in vivo and in vitro, and a synergistic effect can be generated with sorafenib; meanwhile, the anti-proliferation ability is also shown in sorafenib drug-resistant liver cancer. The derivative B12 of the Psammatlysene D has a stronger in-vitro anti-hepatic fibrosis effect, and the C11 has a very weak inhibition capability on hERG (human endothelial growth factor) and has no potential cardiotoxicity. The results show that the Psammaglyene D has relatively strong capabilities of resisting hepatic fibrosis, inhibiting liver cancer development and relieving sorafenib drug-resistant liver cancer, and the Psammaglyene D and C11 can be used as potential lead compounds for the development of anti-hepatic fibrosis and anti-liver cancer drugs, and are finally applied to the treatment of chronic liver diseases.

The present invention relates to the field of liver disease, and more particularly to a method for determining the presence of chronic plus acute liver failure or for determining the risk of developing ACLF in a patient suffering from cirrhosis or a delayed early stage of ACLF. The invention also relates to a method for distinguishing patients suffering from decompensated liver cirrhosis, acute decompensated liver cirrhosis (ADC) or delayed ACLF from patients suffering from early ACLF or ACLF 1, 2, 3, a method for determining the degree of systemic inflammation and a method for determining the presence of a bacterial infection with sepsis.

This invention relates to the use of a recombinant protein ANG in the preparation of medicaments for treating cholestatic liver disease. Specifically, this invention provides the use of the angiopoietin ANG gene, or its protein, or its promoter, for the preparation of medicaments, compositions, or formulations for the prevention, improvement, and / or treatment of cholestatic liver disease. It is particularly effective in treating primary biliary cholangitis and primary sclerosing cholangitis.

The invention belongs to the technical field of biological medicines, and particularly discloses application of a CD44 function inhibitor in preparation of a medicine for preventing or relieving radiation liver injury (RILD). Radioactive liver injury is often caused by hepatocellular carcinoma radiotherapy, and specific targeting drugs are lacked clinically. It is revealed for the first time that whether CD44 molecules on the surface of Kuhu cells are highly expressed after radiation, and the CD44 molecules are key hubs for driving RILD; the invention also provides a CD44 function inhibitor which is a specific targeting drug aiming at RILD, and the action mechanism of the CD44 function inhibitor is to effectively block polarization of radiation-induced Kuptake cells to pro-inflammatory phenotype by inhibiting the CD44 function, so that local inflammatory response, oxidative stress and hepatocyte injury of the liver are relieved. Experiments prove that the CD44 function inhibitor can relieve liver inflammation, improve liver function indexes and reduce liver cell death and tissue pathological damage, and a brand-new and targeted scheme for preventing and treating RILD is provided.

The present invention provides novel 2,4-dinitrophenol (DNP) derivatives and prodrugs thereof as modulators of mitochondrial function. The present invention also provides pharmaceutical compositions comprising the compounds of the present invention and methods for using the same to treat various diseases and conditions associated with or related to mitochondrial dysfunction (e.g., obesity, diabetes, insulin resistance, liver disease, heart or kidney failure, neurodegenerative diseases, and aging-related diseases, including but not limited to sarcopenia, osteoporosis, etc.).

Disclosed is a homogeneous polysaccharide, monosaccharide components of the homogeneous polysaccharide including mannose and glucose; wherein the main chain structure of the homogeneous polysaccharide is an alpha-(1→4)-linked glucose pyranose main chain; wherein the average molecular weight of the homogeneous polysaccharide is 11.1 ± 5.0 kDa. The homogeneous polysaccharide of the present application can be used for preventing and treating chronic liver disease.

The invention discloses an application of gentiopicroside in preparation of a medicine for protecting liver ischemia-reperfusion injury, discusses the protection effect of gentiopicroside on mouse liver ischemia-reperfusion injury, and preliminarily reveals a ferroptosis related molecular mechanism. The invention discloses that gentiopicroside can play a role in protecting HIRI by inhibiting ferroptosis, oxidative stress and inflammatory response, further indicates that gentiopicroside can be further used for preparing a medicine for protecting liver ischemia-reperfusion injury, and meanwhile, the invention discloses the effect of ferroptosis in HIRI, discovers a new therapeutic target, and has a good application prospect. A new thought and a new direction are provided for treatment of liver diseases.

The present application provides a novel thyroid hormone β receptor agonist of formula (I) having better activity, selectivity or safety and the use thereof for preventing or treating diseases related to the action of β receptor agonists, including, for example, obesity, hyperlipidemia, hypercholesterolemia, diabetes, liver diseases (fatty liver, NASH, NAFLD, etc.), cardiovascular diseases (atherosclerosis, etc.), thyroid diseases (hypothyroidism, thyroid cancer, etc.), and the like.

The present application provides a compound of formula (I), or an optical isomer thereof, a pharmaceutically acceptable salt, a solvated form, or a prodrug. The compound may modulate NTCP function for the prevention and / or treatment of HBV / HDV and hepatitis virus-related diseases, bile acid-related cholestasis disorders, metabolic disorders, and / or liver diseases. Additionally, the present application relates to a pharmaceutical composition comprising such a compound and a method for modulating NTCP.

The invention relates to methods of assessing liver disease in a subject by detecting one or more single-nucleotide polymorphisms (SNPs) of the subject and correlating the detected SNPs to the liver disease. The methods may also include a step of implementing a treatment decision, such as monitoring the subject for signs of liver disease, administering a therapeutic agent to the subject, liver transplant, or combinations thereof. The invention also relates to computing devices for assessing liver disease in a subject.

The application provides an optimized lactoferricin peptide, a preparation method thereof and application thereof in preparation of anti-inflammatory and anti-oxidative damage preparations, and belongs to the technical field of biological medicines.The application obtains high-biological-activity lactoferricin peptide by optimizing amino acid sites of lactoferricin B; compared with the original lactoferricin B, the optimized lactoferricin peptide has better anti-inflammatory and anti-oxidative effects, can effectively reduce alcohol-induced oxidative damage, fatty degeneration and apoptosis of liver cells, and promote recovery of liver function.The lactoferricin peptide provided by the application can reduce the elevated serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels by about 25% and 20%, respectively.The application provides an application scheme in development of a new generation of polypeptide drugs for treating alcoholic liver disease, hepatitis, acute lung injury and various inflammation oxidative stress related diseases.

The present invention relates to methods for determining the risk of developing a liver disease based on single nucleotide polymorphism detection. More specifically, the present invention comprises the use of rs3859093, rs34474737, rs10893, rs2070666, rs7087728, rs55907967 and / or rs17846713. The present invention therefore relates to the field of biomedicine.

The invention provides application of a paeoniflorin photoaffinity probe in screening key target protein of paeoniflorin, and relates to the technical field of chemical proteomics. The paeoniflorin photoaffinity probe has a structure as shown in a formula I, and the paeoniflorin key target proteins are 40S ribosomal protein S3 and statin 2. The paeoniflorin photoaffinity probe is applied to screening of the paeoniflorin key target proteins, so that two target proteins combined with paeoniflorin in liver cells are successfully identified; the two target proteins are respectively 40S ribosomal protein S3 (RPS3) and statin 2 (PHB2), and the two target proteins participate in the protection effect of paeoniflorin on the liver, and have the key effects of oxidation resistance, inflammation resistance, immunoregulation and the like in liver diseases.

The present disclosure relates to a drug combination and a method for the prevention and / or the treatment of a liver disease, the combination comprising lanifibranor or a deuterated form thereof and a GLP-1 / GIP / glucagon triple receptor agonist.

The application provides a curcumin composition-FGF21 functional protein co-assembly microparticle applied to liver diseases and a preparation method thereof, and comprises the following steps: extracting turmeric by dynamic warm soaking, obtaining turmeric filtrate after centrifugation, concentration and microfiltration; preparing high-purity curcumin composition through PS-NVP specific purification and 80% ethanol gradient elution; and preparing Curs-FGF21 co-assembly microparticles through oil-water phase assembly and centrifugation by taking a polymer as a carrier, compounding the curcumin composition with FGF21 protein. The microparticle can improve drug stability and bioavailability, realizes long-acting slow release, can regulate liver cell lipid metabolism, reduce liver lipid accumulation and inflammation, significantly improves liver damage and liver fibrosis, and has outstanding liver protection and repair effects. The process is stable and controllable, has outstanding innovation, and provides a brand-new candidate preparation research and development idea and technical scheme for the prevention and treatment of metabolic liver diseases.